imaging Jan 23, 2023 Viewpoint Molecular Targeting Treats First Neuroendocrine Cancer Patients With Radiopharmaceutical Jan 17, 2023 Yantai LNC Biotechnology to Use Sofie Biosciences Imaging Agent to ID Patients for Theranostic Trial Dec 1, 2022 Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Nov 21, 2022 Clarity Pharmaceuticals to Evaluate GRPr-Targeting Radiopharmaceutical in mCRPC Trial Oct 21, 2022 PSMA, Tumor Metabolic Volume May Help Refine Pluvicto Use in Prostate Cancer, Study Suggests Premium Oct 20, 2022 GE Healthcare Educating Docs on Guidelines-Backed Use of Imaging Agent for ER-Positive Breast Cancer Premium Oct 19, 2022 Blue Earth Diagnostics, Siemens Healthineers Partner on Prostate Cancer Theranostics, PET Imaging Oct 14, 2022 EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC Oct 11, 2022 ONI, UPenn Partner on Microscopy-Based CAR T-Cell Therapy Biomarker Research Sep 27, 2022 Optellum Raises $14M in Series A Financing Sep 13, 2022 Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response Jun 22, 2022 Mark Foundation, Johns Hopkins University Invest $10M in Cancer Immunotherapy Research Jun 16, 2022 Ratio Therapeutics Launches to Develop More Target-Specific, Less Toxic Radiopharmaceuticals Premium Jun 10, 2022 Telix Pharmaceuticals, RefleXion Medical to Develop Illuccix-Guided Radiotherapy for Prostate Cancer Jun 6, 2022 VISION Trial Sub-Studies Refine Pluvicto Benefit as Radiopharmaceutical Access Barriers Persist Premium May 26, 2022 UK Researchers ID Potential Biomarker of Response to Herceptin in Overweight Breast Cancer Patients Premium May 16, 2022 Point Biopharma to Launch Phase I Study of FAP-Targeted Radiopharmaceutical in Canada May 11, 2022 NCCN, SNMMI Update Guidelines to Expand PET Imaging Agents for Pluvicto Eligibility May 5, 2022 Novartis Pauses US Pluvicto Production Due to Possible Quality Issues May 5, 2022 Telix Pharmaceuticals Doses First Kidney Cancer Patient in Radiopharmaceutical Trial Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
